Antibody Internalization
Antibody-drug conjugates (ADCs), which have become a new targeted therapy against cancer, consist of an antibody linked to a cytotoxic drug. The ADCs bind selectively to the target cancer cells via the monoclonal antibody portion. Internalization of the ADCs releases the drug to do its damage. This achieves target-specific killing of tumor cells while minizing systemic toxicity of the cytotoxic drug.
AlpVHHs offers a new generation of nano-secondary antibody-drug conjugates linked to MMAE, MMAF, DM1, or Duocarmycin, etc for antibody internalization detection. Using Nano-secondary antibody-drug conjugates (nano-2°ADC) in a cell-based cytotoxic assay is a quick and economical alternative to pre-screening monoclonal antibodies as ADC candidates against tumor cells. Nano-2°ADCs are highly specific with minimally toxicity to cells in the absence of primary antibodies. No obvious change of the primary antibody activity in the presence of the unconjugated secondary antibody.
Nano-secondary antibody-Drug conjugates
AlpVHHs offers a new generation of Nano-Secondary antibody-drug conjugates with MMAE, MMAF, DXD or PBD for antibody internalization assays.
The use of Nano-Secondary antibody-drμg conjμgates (Nano-Secondary ADCs) in cell-based cytotoxicity assays is a rapid and cost-effective alternative for pre-screening candidate ADC monoclonal antibodies against tumor cells.
Nano-Secondary ADCs are highly specific and minimally toxic to cells in the absence of primary antibodies, and there is no significant change in primary antibody activity when the conjμgated secondary antibody is present.
| Code | Description | Applications | Size |
| 023-101-101 | Anti-Human IgG Fc, AlpSdAbs® VHH(VcMMAE ×4) | Internalization Test | 100ug |
| 023-101-102 | Anti-Human IgG Fc, AlpSdAbs® VHH(VcMMAF ×4) | Internalization Test | 100ug |
| 023-101-103 | Anti-Human IgG Fc, AlpSdAbs® VHH(GGFG-DXD ×4) | Internalization Test | 100ug |
| 023-101-113 | Anti-Human IgG Fc, AlpSdAbs® VHH(GGFG-DXD ×8) | Internalization Test | 100ug |
Nano-DT
DT-3C is a commonly used endocytosis detection reagent, but its binding domain is protein G, which will bind to IgG in serum and cause interference. Secondly, the affinity of protein G to different subtypes of mouse and human IgG is different, which will interfere with the result judgment. Nano-DT replaces the protein G binding domain in DT-3C with a high-affinity, high-specificity nanobody that does not bind to bovine IgG.
Nano-DT is an efficient antibody endocytosis detection tool that can be used as a high-throμghput detection tool for pre-drμg evaluation of ADC-related antibodies.
| Code | Description | Applications | Size |
| 001-101-020 | Anti-Mouse IgG, AlpSdAbs® VHH(DT) | Internalization Test | 100ug |
| 023-101-020 | Anti-Human IgG, AlpSdAbs® VHH(DT) | Internalization Test | 100ug |
Nano-pH-sensitive probe
Nano-pH-sensitive probe is a new generation of nanobodies (<15KD) coupled to pH-dependent fluorescent probes for endocytosis detection launched by AlpVHHs. pH-sensitive dyes have no fluorescence excitation outside the cell, but emit bright red or green fluorescence in some acidic environments inside the cell (including phagosomes). Unlike traditional labeling methods using amino or thiol-reactive markers, Nano-pH-sensitive probes, which are site-specifically coupled to pH-dependent fluorescent probes by specific nanobodies, are very stable and compatible with BSA and other stable proteins.
Nano-pH-sensitive probe is a fast and economical antibody endocytosis detection reagent.
| Code | Description | Applications | Size |
| 001-101-014 | Anti-Mouse IgG, AlpSdAbs® VHH(Deep Red630) | Internalization Test | 100ug |
| 023-101-014 | Anti-Human IgG, AlpSdAbs® VHH(Deep Red630) | Internalization Test | 100ug |
